SG11201608240RA - Macrocylic pyrimidine derivatives - Google Patents

Macrocylic pyrimidine derivatives

Info

Publication number
SG11201608240RA
SG11201608240RA SG11201608240RA SG11201608240RA SG11201608240RA SG 11201608240R A SG11201608240R A SG 11201608240RA SG 11201608240R A SG11201608240R A SG 11201608240RA SG 11201608240R A SG11201608240R A SG 11201608240RA SG 11201608240R A SG11201608240R A SG 11201608240RA
Authority
SG
Singapore
Prior art keywords
pyrimidine derivatives
macrocylic
macrocylic pyrimidine
derivatives
pyrimidine
Prior art date
Application number
SG11201608240RA
Inventor
Gaston Stanislas Marcella Diels
Bruno Schoentjes
Matthias Luc Aimé Versele
Didier Jean-Claude Berthelot
Marc Willems
Marcel Viellevoye
Werner Constant Johan Embrechts
Berthold Wroblowski
Lieven Meerpoel
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of SG11201608240RA publication Critical patent/SG11201608240RA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/582Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG11201608240RA 2014-04-03 2015-04-02 Macrocylic pyrimidine derivatives SG11201608240RA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14163443 2014-04-03
EP14183747 2014-09-05
PCT/EP2015/057399 WO2015150555A1 (en) 2014-04-03 2015-04-02 Macrocylic pyrimidine derivatives

Publications (1)

Publication Number Publication Date
SG11201608240RA true SG11201608240RA (en) 2016-10-28

Family

ID=52781117

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201608240RA SG11201608240RA (en) 2014-04-03 2015-04-02 Macrocylic pyrimidine derivatives

Country Status (21)

Country Link
US (1) US10017509B2 (en)
EP (1) EP3126364B1 (en)
JP (1) JP6529513B2 (en)
KR (1) KR102390276B1 (en)
CN (2) CN114213415A (en)
AU (1) AU2015239098B2 (en)
BR (1) BR112016021982B1 (en)
CA (1) CA2942636C (en)
CL (1) CL2016002461A1 (en)
EA (1) EA031246B1 (en)
ES (1) ES2667723T3 (en)
IL (1) IL248005B (en)
MA (1) MA39822A (en)
MX (1) MX369798B (en)
MY (1) MY185491A (en)
NZ (1) NZ725399A (en)
PE (1) PE20161362A1 (en)
PH (1) PH12016501963B1 (en)
SG (1) SG11201608240RA (en)
UA (1) UA118219C2 (en)
WO (1) WO2015150555A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3416957T1 (en) 2016-02-19 2020-11-30 Sprint Bioscience Ab 6-heterocyclyl-4-morpholin-4-ylpyridin-2-one compounds useful for the treatment of cancer and diabetes
JP6997462B2 (en) 2016-02-19 2022-01-17 スプリント バイオサイエンス アクティエボラーグ 6-aryl-4-morpholin-1-ylpyridone compound useful for the treatment of cancer and diabetes
WO2018177889A1 (en) 2017-03-28 2018-10-04 Bayer Aktiengesellschaft Novel ptefb inhibiting macrocyclic compounds
EP3601253B1 (en) 2017-03-28 2021-09-15 Bayer Aktiengesellschaft Novel ptefb inhibiting macrocyclic compounds
ES2910157T3 (en) 2017-08-23 2022-05-11 Sprint Bioscience Ab Morpholinylpyridone compounds
CN116041321A (en) 2017-08-23 2023-05-02 思普瑞特生物科学公司 Pyridinamine-pyridone compounds and pyrimidinamine-pyridone compounds
HRP20220571T1 (en) 2017-08-23 2022-06-10 Sprint Bioscience Ab Pyridylpyridone compounds
EP4001278A1 (en) 2017-08-23 2022-05-25 Sprint Bioscience AB Azaindolylpyridone and diazaindolylpyridone compounds
CN115551868A (en) * 2020-02-18 2022-12-30 特修斯制药公司 Macrocyclic compounds and uses thereof
CN113735879B (en) * 2020-05-27 2022-05-17 百极弘烨(广东)医药科技有限公司 Macrocyclic JAK inhibitor and application thereof
CN113735856A (en) * 2020-05-29 2021-12-03 百极弘烨(南通)医药科技有限公司 Macrocyclic JAK inhibitors and uses thereof
CN118139846A (en) * 2021-09-23 2024-06-04 河南晟翔医药科技有限公司 EGFR small molecule inhibitor, pharmaceutical composition containing same and application of EGFR small molecule inhibitor
KR102613509B1 (en) * 2021-12-15 2023-12-13 환인제약 주식회사 Macrocyclic pyrimidine derivatives, preparation method thereof, and pharmaceutical composition for the prevention or treatment of neurodegenerative disease containing the same as an active ingredient
WO2024078263A1 (en) * 2022-10-09 2024-04-18 药雅科技(上海)有限公司 Preparation and use of macrocyclic heterocyclic compound as egfr inhibitor
WO2024094171A1 (en) * 2022-11-04 2024-05-10 江苏恒瑞医药股份有限公司 Substituted aminopyrimidine compound, preparation method therefor, and medical use thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7151096B2 (en) * 2003-03-05 2006-12-19 Irm Llc Cyclic compounds and compositions as protein kinase inhibitors
EP1997495B1 (en) 2003-03-24 2013-01-02 Axikin Pharmaceuticals, Inc. 2-phenoxy- and 2-phenylsulfanyl-benzenesulfonamide derivatives with CCR3 antagonistic activity for the treatment of asthma and other inflammatory or immunological disorders
JO2785B1 (en) 2003-05-27 2014-03-15 شركة جانسين فارماسوتيكا ان. في Quinazoline derivatives
JP4936897B2 (en) 2003-12-18 2012-05-23 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Pyrido- and pyrimidopyrimidine derivatives as antiproliferative agents
JP4892353B2 (en) 2003-12-18 2012-03-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 3-Cyano-quinoline derivatives having antiproliferative activity
MY169441A (en) * 2004-12-08 2019-04-11 Janssen Pharmaceutica Nv 2,4, (4,6) pyrimidine derivatives
JO3088B1 (en) 2004-12-08 2017-03-15 Janssen Pharmaceutica Nv Macrocyclic Quinazoline derivatives and their use as MTKI
NZ564179A (en) 2005-06-30 2010-09-30 Janssen Pharmaceutica Nv Cyclic anilino - pyridinotriazines as GSK-3 inhibitors
KR101499594B1 (en) 2005-11-16 2015-03-09 씨티아이 바이오파마 코포레이션 Oxygen linked pyrimidine derⅳatives
EP1961149B1 (en) 2005-11-24 2018-08-08 Synchronica plc Method for securely associating data with http and https sessions
AU2008265104B2 (en) 2007-06-21 2013-09-12 Janssen Pharmaceutica Nv Indolin-2-ones and aza-indolin-2-ones
CA2693715C (en) 2007-07-27 2015-10-27 Janssen Pharmaceutica Nv Pyrrolopyrimidines
TW200922556A (en) 2007-08-20 2009-06-01 Glaxo Group Ltd Novel cathepsin C inhibitors and their use
JP5480824B2 (en) * 2008-03-10 2014-04-23 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 4-Aryl-2-anilino-pyrimidines as PLK kinase inhibitors
AU2009256574A1 (en) 2008-06-13 2009-12-17 Novartis Ag 2,4'-bipyridinyl compounds as protein kinase D inhibitors useful for the treatment of IA heart failure and cancer
BRPI1011612A2 (en) 2009-05-28 2019-09-24 Tetralogic Pharm Corp compound, pharmaceutical composition, and methods for inducing apoptosis in a cell, for treating cancer, and for treating an autoimmune disease.
CN102548987B (en) 2009-07-14 2014-04-16 江苏迈度药物研发有限公司 Fluoro-substituted compounds as kinase inhibitors and methods of use thereof
TWI513695B (en) 2009-10-27 2015-12-21 Merck Sharp & Dohme (1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl derivatives

Also Published As

Publication number Publication date
MA39822A (en) 2018-02-06
ES2667723T3 (en) 2018-05-14
EP3126364B1 (en) 2018-02-07
BR112016021982B1 (en) 2022-07-26
JP2017509687A (en) 2017-04-06
EA201692003A1 (en) 2017-06-30
CA2942636A1 (en) 2015-10-08
CA2942636C (en) 2023-03-21
KR102390276B1 (en) 2022-04-22
PH12016501963A1 (en) 2017-01-09
PE20161362A1 (en) 2016-12-17
EP3126364A1 (en) 2017-02-08
MX2016012992A (en) 2016-12-07
BR112016021982A2 (en) 2017-08-15
IL248005B (en) 2018-12-31
UA118219C2 (en) 2018-12-10
CN106164075A (en) 2016-11-23
CN106164075B (en) 2021-11-26
MY185491A (en) 2021-05-19
CN114213415A (en) 2022-03-22
US20170022202A1 (en) 2017-01-26
CL2016002461A1 (en) 2017-06-23
KR20160142316A (en) 2016-12-12
MX369798B (en) 2019-11-21
EA031246B1 (en) 2018-12-28
PH12016501963B1 (en) 2017-01-09
NZ725399A (en) 2023-01-27
AU2015239098B2 (en) 2019-08-01
AU2015239098A1 (en) 2016-09-29
US10017509B2 (en) 2018-07-10
JP6529513B2 (en) 2019-06-12
WO2015150555A1 (en) 2015-10-08

Similar Documents

Publication Publication Date Title
HK1252752A1 (en) Novel pyrazolo pyrimidine derivatives
HK1223100A1 (en) Heterocyclic compounds
IL248005B (en) Macrocylic pyrimidine derivatives
IL253381B (en) 9h-pyrrolo-dipyridine derivatives
ZA201606768B (en) Macrocylic pyridine derivatives
SG11201609205WA (en) Heterocyclyl-butanamide derivatives
PL3131898T3 (en) Fluoroalkylfluorene derivatives
IL248773A0 (en) Naphthyridinedione derivatives
PL3418273T3 (en) Flavagline derivatives
IL248629B (en) Cycloalkyl-linked diheterocycle derivatives
AP2016009506A0 (en) Pyrimidine compound
SI3097076T1 (en) Novel cyp-eicosanoid derivatives
IL251005B (en) Pyrido-oxazinone derivatives
GB201414116D0 (en) Benzodiazepine derivatives
SG11201803357TA (en) Pyrimidine derivative
PL3119744T3 (en) 2-cyano-3-cyclopropyl-3-hydroxy-n-aryl-thioacrylamide derivatives
IL248900A0 (en) Pyrazine derivatives
GB201416351D0 (en) Heterocyclic derivatives